Article
A case-control study of a combination of single nucleotide polymorphisms and clinical parameters to predict clinically relevant toxicity associated with fluoropyrimidine and platinum-based chemotherapy in gastric cancer.
BMC cancer - 16 Sept 2021
Cordova-Delgado Miguel, Bravo María Loreto, Cumsille Elisa, Hill Charlotte N, Muñoz-Medel Matías, Pinto Mauricio P, Retamal Ignacio N, Lavanderos María A, Miquel Juan Francisco, Rodriguez-Fernandez Maria, Liao Yuwei, Li Zhiguang, Corvalán Alejandro H, Armisén Ricardo, Garrido Marcelo, Quiñones Luis A, Owen Gareth I
Abstract excerpt
BACKGROUND: Fluoropyrimidine plus platinum chemotherapy remains the standard first line treatment for gastric cancer (GC). Guidelines exist for the clinical interpretation of four DPYD genotypes related to severe fluoropyrimidine toxicity within European populations. However, the frequency of these single nucleotide polymorphisms (SNPs) in the Latin American population is low (< 0.7%). No guidelines have been...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.